

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
August 3, 2022
MINUTES

1. Call to Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, August 3, 2022.

2. Welcome

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Divya Ahuja, MD
Kimberly Rudd, MD
Kelly Barth, MD
Erika Tillery, PharmD

Edward Behling, MD
Jony Bolinger, MD
Thomas Phillips, RPh
Patricia Witherspoon, MD

Duncan Norton, MD
Phillip Mubarak, MD
Gregory Browning, MD

SC DHHS Staff:

Cheryl Anderson BS, RPh
Brandie Crider
Nicole Wetherton, JD
Janet Giles
Ashley Sirianni, DNP, FNP-BC

Magellan Medicaid Admin:

Lisa Correll, PharmD
Lori Ash

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, May 4, 2022

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

Company	Speaker	Drug/Class
Novo Nordisk	Jeff Goforth, PharmD	GLP1-1 Receptor Agonists, Injectable
Lilly	Alexandra Wallem, PharmD	GLP1-1 Receptor Agonists, Injectable

C. Drug Classes for Review

Classes for Re-Review

- GLP1-1 Receptor Agonists, Injectable
- Epinephrine, Injectable

Classes for Review

- Methotrexate, Injectable
- NSAIDs, Topical

The chart below represents the recommendations from the P & T Committee:

GLP1-1 RECEPTOR AGONISTS, INJECTABLE	
Preferred	Non-Preferred
Ozempic®‡	Adlyxin®
Trulicity®	Byetta®
Victoza®	Bydureon BCise®
EPINEPHRINE, INJECTABLE	
Preferred	Non-Preferred
Epinephrine 0.3, 0.15mg	Epinephrine 0.3, 0.15 mg AG
EpiPen®/EpiPen Jr®‡ (0.3,0.15mg)	Epinephrine 0.3, 0.15mg generics
	Symjepi®
METHOTREXATE, INJECTABLE	
Preferred	Non-Preferred
Methotrexate vial/PF vial‡	Otrexup®
Rasuvo®‡	Reditrex®
NSAIDS, TOPICAL	
Preferred	Non-Preferred
Diclofenac sodium 1% topical gel‡	Diclofenac epolamine
	Diclofenac sodium, topical solution
	Pennsaid® 2% pump
	Voltaren®

‡ Added as “Preferred”

+ Moved to “Non-Preferred”

5. **Old Business**

None

6. **New Business**

Lisa Correll presented new drugs to market and therapeutic classes for P&T Committee review.

7. **Resolved Items**

Classes for Re-Review

GLP1-1 Receptor Agonists, Injectable

Epinephrine, Injectable

Classes for Review

Methotrexate, Injectable

NSAIDs, Topical

8. **Closing Comments**

The next meeting will be held Wednesday, November 2, 2022.

9. **Adjournment**

The meeting adjourned at 4:50 p.m.